New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most

There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Sickle Cell Anemia Genetic Engineering Blood Genetics and Heredity Income Inequality Bone Marrow Drugs (Pharmaceuticals) Therapy and Rehabilitation Developing Countries Crispr (DNA) Transplants Stem Cells Food and Drug Administrati Source Type: news